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The Lancefield M-typing system, a typical
serologic system based on antigen-antibody
reactions, is dependent on the preparation of
type-specific antisera and extraction of a protein
identified as M protein on the surface of group A
streptococci (GAS) (1). The antisera against the
M-protein antigens are produced with whole-cell
streptococcal vaccines used to immunize rabbits.
Acceptable antisera contain specific-precipitin
antibodies and type-specific antibodies that must
enhance the phagocytosis of the strain used to
immunize the rabbit (2,3). The precipitin
antibodies are made specific by absorption of the
serum with streptococcal cells to remove the
carbohydrate group antibodies and any cross-
reactive precipitin antibody to heterologous
M-type strains. Each rabbit antiserum is tested
for reaction with antigens of all known M types.
Approximately half of GAS strains produce
an apoproteinase, an enzyme that causes
mammalian serum to increase in opacity. This
reaction is called the serum opacity factor
reaction, and the responsible enzyme is referred
to as opacity factor (OF). The OF enzymes are OF
type-specific because each M type that produces
OF can induce type-specific OF antibodies that
can be used in OF inhibition tests (3,4).
Preparation of the OF antisera and specific
details of the OF tests are described elsewhere
(3,4). Some laboratories have used OF typing to
predict M types in epidemiologic investigations.
Even though it is not uniformly agreed that OF
typing antisera results should be reported as M
or provisional M-typing results, anti-OF antisera
in many situations predict the M type in a type-
specific manner. For reporting purposes, if
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cultures are identified with M- or OF-typing
antisera, they should be identified as M type or
OF type.
Reference strains used to prepare the M
antisera (several of which were originally
described by Griffith in 1935) were historically
obtained from the Lancefield collection,
Rockefeller University, New York; however
more recently, reference strains have been
available from other reference laboratories.
M-types 1 through 51 were designated in the
laboratory of Dr. Rebecca Lancefield between
1928 and 1945. M-types 52 through 81 were
submitted by various investigators to reference
laboratories in Atlanta, London, New York, and
Prague between 1965 and 1976 for confirmation.
Some laboratories believe that certain strains in
the Lancefield collection do not adequately
express M protein and are unsuitable for the
production of M-type antiserum. Preparing M-
type antiserum or a typing system accurately
related to the Lancefield system requires
documented reference strains from one of the
internationally recognized reference laborato-
ries.2
In the Lancefield typing system, strains
representing types 7, 16, 20, and 21 (originally
described as Griffith) are not GAS but belong to
groups C and G. M-type 10 is the same serotype
as M12, M-type 24 is the same as M45, and M-
type 35 is the same as M49; thus, designations of
serotypes 7, 10, 16, 20, 21, 35, and 45 are not
included in the Lancefield M-typing system 1 to
81 for GAS.
The emm gene of S. pyogenes is the gene that
encodes the M protein. The M protein,
responsible for the bacteriums capacity to resist
phagocytosis, is a major virulence factor in GAS.
The 5' ends of emm genes are highly
heterogeneous and encode for the serotype
specificity used for the M-typing system
developed by Dr. Lancefield in 1928 (1).
Producing type-specific M-typing antisera is
difficult and specialized; no attempt has ever
been made to produce them commercially, and
only a few international reference laboratories
prepare them. The resurgence of rheumatic
fever cases in the United States and the
emergence of severe infections (streptococcal
toxic shock and necrotizing fasciitis) caused by
GAS in the 1980s and 1990s indicated the need to
reassess typing strategies for GAS. Since
production of M-type precipitating antisera is
very expensive and labor-intensive, the potential
usefulness of a nonserologic typing system for
GAS sequencing the 5' end of the M protein
(emm) gene toward a molecular-based typing
system was examined.
emm Typing System for GAS
Before an emm genotype-based typing
scheme was developed for GAS, the nucleotide
sequence at the 5' ends of emm genes had been
reported for many strains representing M-types
1-81 and several provisional M types (PT) (5,6).
However, it was not always evident that true
reference strains had been used. The knowledge
gained from these studies provided the impetus
for exploring the feasibility of an emm-based
genotyping system. Subsequent studies based on
sequencing the 5' emm genes from GAS reference
strains and clinical culture specimens have now
been published (7,8). In all studies involving
emm sequence typing, 160 to 660 bases were
sequenced from the 5' terminal end of the emm
gene. The methods of emm sequencing and emm
gene amplicon profiling restriction pattern
techniques have been described (7,8). Two
isolates are regarded as sharing the same emm
sequence type if they are ³ 95% identical over
their 5' end 160 nucleotides (includes approxi-
mately 50 bp of the moderately conserved leader
peptide-coding region), allowing for one frame
shift or in-frame insertion/deletion of no more
than seven codons (8). The results of emm gene
sequencing of Dr. Lancefields reference strains
types 1 to 51 and reference strains of M-types 52
to 81, submitted to the Centers for Disease
Control and Prevention (CDC) Streptococcus
Reference Laboratory as potential new M types
from 1967 to 1976 by various international
investigators, are summarized below.
The 5' end emm sequences of the following
CDC M-type reference strains matched the
following sequences in GenBank that were
submitted by other investigators: Types 1, 2, 3, 4,
5, 6, 8, 9, 11, 12, 14, 15, 17, 18, 19, 22, 23, 24, 25,
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47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60,
61, 62, 63, 64, 65, 66, 72, 73, 74, 75, 76, 77, 78, 80,
81. The accession numbers for these and many
other emm sequences deposited in GenBank are
listed in references 5-8 and at http://www.cdc.gov/
ncidod/biotech/infotech_hp.html.
The 5' emm sequences from the CDC
reference strains of GAS for the following M
types were submitted to GenBank: M-types 13
(AF025950), 32 (L47325), 34 (L47324), 38/40
(L46817), 42 (L46799), 67 (AF025949), 68
(AF025948), 69 (AF035838), 70 (AF035838), 71
(L46652). The 5' emm sequences that were
different from those submitted to GenBank by
previous investigators (6) are M-types 13, 67, 68,
and 79. For M-type 13, the emm sequence in
GenBank was not from a recognized Lancefield
typing strain; emm sequence AF025950 should
be considered the emm sequence for Lancefield
M-type 13. For M-types 67 and 68, the emm
sequences in GenBank did not match those from
CDC. The reasons for this are unknown;
however,  emm sequence AF025949 (M-type 67)
and emm sequence AF025948 (M-type 68) were
obtained from the reference strains submitted to
CDC by the investigators who originally
described these M types. For M-type 79, the emm
sequence obtained by the CDC investigators
matched the emm sequence in GenBank labeled
M-type 80. Personal communication with the
investigators who submitted the emm sequences
for M-types 79 and 80 indicated a transcription
error during submission of the sequences.
Sequence U12004 is the correct sequence for M-
type 79. The emm sequences from the CDC
reference strains representing these four M
types were confirmed by an independent
laboratory.
CDC has additional data on emm typing of
more than 1,500 GAS isolates from population-
based studies, as well as random cultures from
the United States and several other countries.
Nearly 100% of the cultures could be genotyped
by the emm typing system. In addition to
determining the emm types of reference strains
of  M-types 1 to 81, several provisional type
strains as well as new sequence type strains were
typed by the emm typing procedure. Only one of
more than 1,500 GAS isolates could not be emm
typed by current methods. The emm sequence
type of clinical isolates representing 35 distinct
serotypes match the emm sequence type of the
corresponding reference strainincluded in this
set of analyses are clinical isolates that
underwent M or OF serotyping at one of the
internationally recognized reference laborato-
ries or elsewhere (8;9; B. Beall and D. Bessen,
unpub. data).
The historical correlations between T type,
OF reaction, and M type are largely unchanged
when  emm sequence type is substituted for
M type (3,4,7,8). Because this observation is
based upon the analysis of >3,000 clinical
isolates, the T type and OF reactions together
constitute an invaluable second-tier method for
further confirmation of the grouping of closely
related isolates, as well as for resolution of
unrelated sets of organisms (R. Beall and R.
Facklam, unpub. data).
When comparing a phenotypic-based typing
scheme to a genotypic-based scheme, complete
concordancy is not expected. Although for most
types the M serotype is paired with a unique
emm sequence type, there are several discrepan-
cies. In five well-documented instances, 5' end
emm sequences are >95% identical for two
distinct M serotypes: M-types 27L and 77, 38 and
40, 44 and 61, 50 and 62, and 65 and 69 (10). The
molecular basis for a lack of concordancy can
differ for each unique M-type/emm-type pair. A
few critical nucleotide substitutions at the 5'
emm region could result in new, dominant
antigenic epitopes that lead to the generation of
a distinct serologic type. Alternatively, emm
genes can occasionally undergo horizontal
exchange and move onto a new genetic
background, as appears to be the case for emm44
and  emm61 (6); in this instance, additional
dominant, polymorphic antigens may exist that
can also be detected by M-typing sera. For the
five examples cited above, introduction of a
second typing scheme (T-agglutination and OF
reaction) has proven useful in distinguishing
between pairs displaying identical emm se-
quence types, but distinct M serotypes.
The discriminatory power of the genotypic
emm sequence-typing scheme approximates that
of the phenotypic M-serotyping scheme. For
most M serotypes, there is a one-for-one
relationship with a unique emm sequence type.
The selection of 95% sequence identity as the
cutoff value for defining the emm sequence type
is based on empirical measures that best match
the level of resolution achieved by M serotyping.
In several examples, the emm sequence of one
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level of sequence identity (but <95%) to a second,
unique emm-type/M-type pair. For example, the
emm3 and emm31 sequences share 91.3%
identity over their first 160 bases; emm2 and
emm73 are 89% identical over their first 160
bases of 5' end sequence, and this similarity is
increased to 92.3% identity over their first 326 5'
bases. Conceivably, certain genetic changes,
such as a single bp insertion in the emm
hypervariable region followed by a single bp
deletion much farther downstream, could alter
the reading frame of the gene and hence the
antigenic structure and serotype of the emm
gene product; however, this kind of variant has
rarely been encountered in CDC surveys. Other
genetic changes, such as synonymous substitu-
tions, have no effect on phenotype. In some
instances a single deletion or insertion of seven
or fewer codons within the hypervariable 5' end
160 bp had no effect on the predicted M serotype
(B. Beall, unpub. data). Therefore, an emm gene
with less than 95% sequence identity to other
emm genes may confer a new M serotype
specificity. Thus, two isolates are regarded as
sharing the same emm sequence type if they are
>95% identical over their first 160 nucleotides,
allowing for one frame shift or in-frame
insertion/deletion of no more than seven codons
(8). The 95% identity cutoff is not expected to
match perfectly what can be achieved by
serologic methods.
Most of the GAS isolates that are deemed
nontypable by serologic methods can be
genotyped through emm sequence determina-
tion. Furthermore, the M serotype does not
always match the emm sequence-type (9,11).
However, among the hundreds of strains
analyzed by the streptococcal reference labora-
tory at CDC no discrepancies were observed
between M serotype and emm sequence type.
The full extent of putative M-serotype/emm
sequence-type discordancies is not known, and
the explanations for such a lack of congruency
are numerous. A more complete understanding
of the basis for discrepancies will be forthcoming
as the emm sequence-typing method becomes
more widely implemented.
The  emm-typing system is a useful and
reliable epidemiologic tool for subdividing GAS.
Because it is independent of emm gene
expression and can often discriminate between
biologically distinct isolates that may be only
weakly antigenic or nontypeable, emm sequence
typing has the potential to classify isolates that
have been difficult to type by serologic methods.
Designation of M, Provisional M, and emm
Sequence Types
GAS strains fall into three categories:
Validated M types, provisional M types, and
emm sequence types. If a laboratory has
prepared antiserum to an unknown strain and
the serum has type-specific precipitating
antibodies, as well as bactericidal antibodies
directed to that strain, verified by one of the six
original reference laboratories, an M-type
designation can be assigned to that strain. If two
laboratories (at least one being one of the six
reference laboratories) produces type-specific
precipitating and bactericidal antiserum to the
strain, the strain also qualifies as a new M type.
When a laboratory has prepared antiserum
as described above to an unknown strain but the
specificity of this antiserum has not yet been
confirmed by a second reference laboratory, that
strain is designated a provisional type. The
requirements for conventional validation of new
M types will be described elsewhere. A third
category are sequence types or emm types, which
are strains typed by sequencing the emm gene. If
cultures are identified by emm sequencing, they
should be reported as emm type.
Validation Procedures and Nomenclature
of New emm Sequence Type Strains
Published  emm sequences from studies
conducted in New Zealand and Australia
included several new emm sequences included in
GenBank (12,13). In addition, data from the CDC
studies (B. Beall and R. Facklam, http://
www.cdc.gov/ncidod/biotech/infotech_hp.html)
indicated that more than 30 unknown emm
sequences were identified among the 1,500
isolates of GAS that had been emm sequenced. A
working group of representatives of each of the
six international reference centers in Canada,
New Zealand, Czech Republic, United Kingdom,
and United States, was charged with establish-
ing a definitive protocol both for submission of
new  emm sequences and for subsequent
validation of new emm types. As an interim
measure, unique 5' end emm sequences proposed
as new emm types must be confirmed by a second
laboratory; at least one of the two laboratories
should be the streptococcal reference laboratory
at CDC. If the uniqueness of the emm sequence251 Vol. 5, No. 2, AprilJune 1999 Emerging Infectious Diseases
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can be confirmed by the second laboratory, the
original investigator or one of the confirming
laboratories will submit the findings to the
Working Group, which will determine whether
the strain should be assigned a new emm type
number (e.g., emm94). In addition to sequence
uniqueness, additional factors may be consid-
ered by the working group when making this
decision; for example, previous requirements for
assigning regular M- and provisional M-type
numbers to strains were restricted to strains of
particular clinical significance or to those
occurring in a population with significant
frequency. Another remaining unresolved issue
is whether or not all new emm reference strains
should actively express M protein. A lack of
surface expression of this emm gene product will
preclude any possibility for correlation of emm
type with classic serologic type or subsequent
evaluation of biological significance. The
relationship of emm sequence to biological
function needs to be further explored.
CDC has validated six emm sequences
submitted to GenBank by Australian investiga-
tors (12-14) and one emm sequence from a strain
submitted to CDC by an investigator in the
United States (15); these sequences should all be
considered for official status as new emm types.
Four additional isolates were examined at the
CDC laboratory for which emm sequences had
been submitted to GenBank (12-14). Strains
STBSB75, ST1293, ST87/156, and STNS27 were
shown to have the same emm types as M-type 70,
M-type 76, PT2110, and PT5757, respectively.
Therefore, these four emm sequences should not
be accepted as new emm types, and their
sequences should be reidentified in GenBank.
CDC has identified 10 new emm types from
population-based studies of GAS invasive
disease (7,8, unpub. data). In addition, eight new
emm sequences from Brazil, six from Malaysia,
three from Papua New Guinea, three from India,
two from Ethiopia, two from Gambia, and one
each from New Zealand and Chile have been
confirmed by a second laboratory for emm
sequence uniqueness, for 36 potentially new
emm types.
List of Reference Strains
The WHO Collaborating Laboratory for
Reference and Research on Streptococci in
Prague has prepared a database of the reference
type strains to be used for research and
antiserum production from information provided
by the six international Reference Centers in
Canada, New Zealand, Czech Republic, United
Kingdom, and United States. Although all the
reference strains on the list at one time had
demonstrated survival in the in vitro bacteri-
cidal test (presumably reflecting functional M
protein), the reference strains should be retested
for survival in the bactericidal test before use in
research. Dr. Lancefields strains types 1 to 50
are listed at http://www.rockefeller.edu/vaf/
Because listing of type strains may be
slightly different for each culture collection,
when cultures are obtained, the strains should
be properly identified. The strains for reference
types 1 to 50 should be traced to the Lancefield
collection, from which the M-typing system was
derived. In the past, if a reference strain lost the
capacity to express M protein on the bacterial cell
surface, that strain was passaged in vivo and
selected for the increased presence of M protein;
therefore, many derivatives of the original
reference cultures are in use by the reference
laboratories, and none are known to have
undergone change in their emm gene nucleotide
sequence. The American Type Culture Collection
(ATCC) has Lancefields strains 1 to 50, the UK
National Collection of Type Cultures has types 1
to 81, as well as the provisional types, and the
Czech Culture Collection in Prague also has
types 1 to 81 on deposit. Reference cultures 51 to
81 have been deposited in the ATCC by the CDC
investigators who will also deposit the provi-
sional type strains shortly. Plans are to continue
the deposition of cultures of new emm types as
they are confirmed.
Additionally, the CDC Streptococcus Labora-
tory has established an emm-type database at
http://www.cdc.gov/ncidod/biotech/
infotech_hp.html for use as a sequence
comparison tool and additional documentation of
all of the verified M and emm types. The
database contains detailed information on the
CDC method of emm typing and provides
additional background on each reference strain
and most known emm sequence types. Sequence
comparisons can be done by using BLAST (Basic
Local Alignment Search Tool). The data are
prereviewed for errors and discrepancies, and all
newly deposited emm-types are first verified
directly by the CDC reference laboratory. At this
time, until a complete validation protocol is
established, investigators who discover new252 Emerging Infectious Diseases Vol. 5, No. 2, AprilJune 1999
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Table. Recommended action for M and emm
designation for provisional M typesa
Provisional CDC ID New emm
type ID number number or M type
PT180(UK)b NCTC12062 SS-1395 82
PT2110(UK) NCTC12064 SS-1400 83
PT2233(UK) R75/2233 SS-1449 84
PT2612(UK) R76/2612 SS-1447 85
PT2631(UK) R76/2631 SS-1448 86
PT2841(UK) NCTC12065 SS-1399 87
PT3875(UK) R67/3875 SS-1455 88
PT4245(UK) NCTC12067 SS-1397 89
PT4931(UK) NCTC12068 SS-1396 90
PT5757(UK) NCTC12056 SS-1398 91
PT5118(NZ) SS-1460 92
PTPotter41(UK) R76/2631 SS-1493 93
aFor definitions of M and emm designations, see section in
text, Designation of M, Provisional M, and emm Sequence
Types.
bAbbreviations; UK= United Kingdom, NZ= New Zealand.
emm sequence types should submit their isolates
to the CDC Streptococcus Laboratory to confirm
uniqueness. As a first step, investigators should
search the CDC database for emm sequences;
Genbank can be used as a second step, since it is
always possible that neither database will
necessarily have all known emm sequences of
GAS at any given time. Furthermore, the CDC
database will include the accepted emm type
designation for those types, whereas a possible
incorrect  emm sequence may have been
submitted to GenBank by an investigator.
Validation of Provisional M Types to New
M and emm Types
The Table lists the provisional M-type
strains and the status of validation. Collabora-
tive investigations involving the six reference
laboratories included several other provisional
M-type strains and has confirmed the following:
PT179 fulfills all the phenotypic criteria for an M
type; however, only anti-OF serum has been
prepared. Therefore, the status of this strain as a
potential new M type remains on hold until
further supporting data can be provided.
PT4854, Colindale Laboratory, United Kingdom
(UK), had a closely matching emm type as M-
type 43; this finding correlated to serologic tests
at CDC and UK laboratories as M-type 43 that
demonstrate that both strains reacted with M43
typing antiserum. PT3800, Prague, Czech
Republic (CZ), has the same emm type as M-type
65, which correlated to serologic tests performed
at the National Streptococcus Laboratory in
Edmonton, Canada, showing that both strains
reacted with M65 typing antiserum. PTYE327
(CZ) has the same emm type as PT2841(UK),
which correlates to serologic tests performed in
both the Colindale and Prague laboratories.
PT1437, Porirua Laboratory, New Zealand (NZ),
has the same emm type as PT4245 (UK), which
correlates to serologic tests performed in both the
UK and NZ laboratories. ST2974.95 (CDC) has
the same emm type as PT5118 (NZ). ST2974.95
was shown to be PT5118 in serologic tests
performed in the Porirua Laboratory. In
summary, PT4854, PT3800, PTYE327, PT1437,
and ST2974.95 should be identified as emm43
(M43), emm65 (M65), emm87 (M87), emm89
(M89), and emm92, (M92) respectively. The
sources of most provisional types were first
documented in 1985 (16).
The following emm types were isolated from
patients with severe invasive disease in the
United States; emm82, emm83, emm86, emm87,
emm88,  emm89, and emm92. These isolates
comprised 12.7% of all isolates identified during
these studies. Types emm82, emm85, emm87,
and  emm89 were associated with epidemic
investigations in the United States. Many of
these new emm types were also identified from
other countries, including Argentina, Brazil,
Bulgaria, Chile, Colombia, Denmark, India,
Korea, Malaysia, New Guinea, and Poland.
Other reference laboratories have reported these
new M types (by using provisional type
identifiers) in a variety of infections, including
rheumatic fever and acute glomerulonephritis
(17,18).
An External Quality Assurance Typing
Program among International Reference
Laboratories
At the request of the World Health
Organization (19), a quality assurance program
on GAS typing has been established by the
Central Public Health Laboratory, London,
United Kingdom. Ten GAS isolates were
examined by six different laboratories, and the
results of the first distribution showed a very
good correlation between laboratories. Emm
typing by one laboratory correlated very well
with M typing by the other five laboratories.
Only minor differences were noted among the T-
and OF-typing results; no errors were found
among the M-typing results. Responsibility for253 Vol. 5, No. 2, AprilJune 1999 Emerging Infectious Diseases
Synopses
sending 10 cultures to the other five centers
twice a year would be rotated among the six
reference centers and a report of the quality
assurance program will be presented at the next
International Lancefield Society meeting in New
Zealand in the fall of 1999.
Dr. Richard Facklam is chief of the Streptococcus Labo-
ratory, Division of Bacterial and Mycotic Diseases Divi-
sion, National Center for Infectious Diseases, CDC. His
major fields of interest include improvement in labora-
tory procedures for the diagnosis of acute respiratory
tract infections, taxonomy of streptococci and related
gram-positive cocci, identification of virulence factors
associated with bacterial respiratory pathogens, and de-
velopment of new systems for epidemiologic study of
the transmission of bacterial respiratory pathogens.
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